280 likes | 464 Views
Innovation in Life Sciences The View from the Bench. Chris Mason University College London. Life Sciences Innovation. What is it? How is it produced in universities? Basic science + translation Barriers to academic innovation In addition to the scientific pursuit
E N D
Innovation in Life SciencesThe View from the Bench Chris Mason University College London
Life Sciences Innovation • What is it? • How is it produced in universities? • Basic science + translation • Barriers to academic innovation • In addition to the scientific pursuit • If and how scientists think about regulation? • If and how scientists think about end products?
What is Life Sciences Innovation? • Satisfy genuine “market” need • Incremental step versus step change • Disruptive technology • Ethically acceptable • Ability to be translated/commercialized • Ability to eventually produce a safe, effective product at a price acceptable for routine clinical practice
How is Life Science Innovation Produced in Universities? • Nature + Nurture • World-Class Scientists • World-Class Support + Infrastructure
1-2 mm biopsy 2-3 weeks growth Healthy eye T-E Cornea Select stem cells Remove scar tissue Adult Stem Cell Therapy Damaged eye Before operation After operation
Barriers to Innovation • Funding • Time • Complexity – Challenges of multi-disciplinary research • Academic demands • Patenting issues • Academia/industry linkage • Basic science versus translation
Academia/Industry Linkage • Academia-commercial collaboration challenging but encouraged • Technology Strategy Board • Unidirectional travel only (UK) • Fear of IP reach-through • Inappropriate valuation/expectation of academic IP • Pieces of jig-saw only • Lack of suitable UK partners/companies
Funding • Cost of life science research +++++ • Full Economic Cost • Grants • Novel but not blue sky • Hypothesis driven • Proof of concept required/Pilot study • ?Available funding
Seed Funding • Spin-out company funding/Seed funding • Pier not a bridge • Lack of follow on funding – “Valley of Death” • Angel + VC • Need to develop technology for longer… • Incubate in university labs • ?Funding mechanism • Not hypothesis driven
International Collaborative Funding • Challenging but increasingly possible • EU Framework Funding • International Stem Cell Forum • CIRM/MRC – MoO • Complex IP issues • Challenging + time consuming to initiate + manage
Time • Life science experiments – Long duration • Multiple repeats/Statistically significant • Grant application time-lines – Long • “Miss the boat” • Time to commercial application – Decades • Time to translation – Many years…
Complexity – Challenges of Multi-Disciplinary Research • Multi-disciplinary life science becoming the norm • Funding challenges • Who is responsible/Cross council funding • Falling in the cracks • Management of grant inc. timing complex • Risk of being service provider • IP – Who owns?
Academic Demands • Increasing demand to measure output • RAE • Pressure to publish • Increasing student load/expectation • Less than 25% grant applications successful • Shortage of postdoc talent • Challenge of competing with industry/city
Patenting Issues • Misunderstood by scientists +++++ • Publish versus patent • Time consuming • Lack of integration scientist/IP department • Too little incentive plus not part of RAE output cf peer-reviewed papers • Infrastructure demands • Keeping compliant lab books • Time-line • Patent applications frequently dropped - £££ • Time to develop versus patent life
Basic Science Versus Translation • What exactly is “translation”? • Basic science – THE BASIS of university research • Funding only for hypothesis driven research • Publication challenges • Lack of joined up thinking • Science, Translation, Commercialization • UCL/LBS collaboration • PhD/MBA
RESEARCH TRANSLATION Must Collaborate Early RESEARCH TRANSLATION
Science + Translation Mike Lester
Regulation • Basic science - Compliance required • Paperwork +++ • Translation • Good Laboratory Practice (cGMP) • Good Clinical Practice (cGCP) • Good Manufacturing Practice (cGMP) • £££££ + challenging to fund • Time consuming (No RAE value) • Service not research BUT ESSENTIAL
University Hospital GMP Facility Collaboration with Julie Daniels, UCL IoO/Moorfields Eye Hosp.
Clinical Trials • Time consuming + complex to set up • Lack of university GMP resources • CMOs expensive + slow • NHS – not an easy environment for research • Service driven • Funding challenging • Negative results – Hard to publish
End Products • Innovation or just fascinating science? • Medical device c.f. biopharmaceutical • Timescale • Cost • Commercialization cycle e.g. MAbs • Product or service? • Commercial or imbedded?
How is Life Science Innovation Produced in Universities? • Nature + Nurture • World-Class Scientists • World-Class Support + Infrastructure
How is GREAT Life Science Innovation REALLY Produced in Universities? • Chance • Collaboration • Cash
Innovation in Life SciencesThe View from the Bench Chris Mason University College London